EGFR and neoplasm: Our data suggest that downregulation of ALIX provides a mechanism for enhancing both EGFR activity and PD-L1-mediated evasion of anti-tumor immunity in BLBC, driving cell-autonomous and non-cell-autonomous mechanisms of tumor survival.